Maximizing Benefits With the Medication Use Evaluation Process

Davis, Sondra; Rungruangphol, Patra D.; Gibson, Caitlin M.

doi:10.1177/0018578718775330

Cited by 4 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the factors affecting the misuse of medications will enable the health providers in the implanting program to prevent inappropriate use of them, and medication use evaluation (MUE) is the cornerstone in this manner. [21] Limited worldwide availability of IVIG, increasing the demands for unlicensed use, and escalating costs, in addition to possible adverse reactions and inadequate information for IVIG use, especially in the Middle East, has been remained the evaluation of IVIG misuse as one of the priorities of MUE for several years. [91517] Therefore, this study was designed to describe the use of IVIG in one of the largest academic tertiary referral hospitals in a developing country in the Middle East.…”

Section: Discussionmentioning

confidence: 99%

Predicting Factors for the Pattern of Intravenous Immunoglobulin Utilization in a Middle Eastern University Hospital

Fakhari

Farsaei

Sabzghabaee

2018

Journal of Research in Pharmacy Practice

View full text Add to dashboard Cite

Objective:The dramatic increase in the consumption of intravenous immunoglobulin (IVIG) products in nonapproved indications, its high cost, and the severe shortage has developed the concerns of its irrational utilization, especially in the Middle East countries. Therefore, this clinical study attempts to describe the pattern of IVIG administration in one of the largest hospitals in Iran and find the variables associated with inappropriate IVIG utilization.Methods:This cross-sectional medication utilization study was conducted in one of the largest referral hospitals in Iran. Random IVIG administrations were assessed from different wards for 9 months. Different data were collected to evaluate the pattern of IVIG administration and find variables, which could predict this behavior.Findings:IVIG was prescribed for approved indications in 72% of 201 patients recruited in our study. Although, the rate of drug administration was appropriate in most of the study population, hydration and pre-medication were unsuitable in more than one-third of the patients. Among the variables analyzed to find the factors affecting the misuse of IVIG, female gender, older age of patients, and longer time to start IVIG administration due to hospital admission were statistically significant in the multivariate model.Conclusion:Despite the fact that inappropriate use of IVIG was confirmed in less than 30 % of its utilization for the studied patients, it caused a potential risk of treatment complications and a notable and unjustifiable burden of unnecessary costs for this University hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting Factors for the Pattern of Intravenous Immunoglobulin Utilization in a Middle Eastern University Hospital

Fakhari

Farsaei

Sabzghabaee

2018

Journal of Research in Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…MUEs are quality improvement monitoring tools that can be adapted to provide real-world evidence of utilization of biosimilars. 82,83 MUEs help to identify cycles of improvement in pattern of prescribing, fill in practice-gaps about uncertainty of patients’ response, and answer questions about effectiveness and safety outcomes associated with switching to biosimilars for stable patients. 82,83 A quasi-experimental study using a pre-post design is a useful approach to compare outcomes for the same patients before and after the introduction of a biosimilar.…”

Section: Key Elements To Consider In Evaluating Biosimilarsmentioning

confidence: 99%

“…82,83 MUEs help to identify cycles of improvement in pattern of prescribing, fill in practice-gaps about uncertainty of patients’ response, and answer questions about effectiveness and safety outcomes associated with switching to biosimilars for stable patients. 82,83 A quasi-experimental study using a pre-post design is a useful approach to compare outcomes for the same patients before and after the introduction of a biosimilar. 84 Since there is frequent under reporting of adverse drug reactions, MUEs may provide valuable information on hypersensitivity, infusion reactions, immunogenicity, cross-immunogenicity, or loss of efficacy by gathering long-term efficacy and safety data using EHRs.…”

Section: Key Elements To Consider In Evaluating Biosimilarsmentioning

confidence: 99%

An Institutional Guide for Formulary Decisions of Biosimilars

et al. 2022

View full text Add to dashboard Cite

Biologics have changed the landscape for the management of many debilitating chronic diseases but account for a significant expenditure of medications globally. Fortunately, advances in technology paved the way for the introduction of biosimilars, which are highly similar to the originator biologics. In the quest to reduce the budget impact of biologics, organizations have begun to adopt biosimilars. Institutions evaluating biosimilars for inclusion in the hospital formulary must make informed formulary decisions by conducting a thorough review of key elements for evaluation of biosimilars and address the multidimensional aspects during the selection process of different biosimilar products. Therefore, we aim to present an institutional guide of these elements to inform formulary decisions. These key elements include biosimilar evaluation for formulary addition; regulatory approval; substitution, interchangeability, and switching; extrapolation; product characteristics, manufacturing, and supply chain issues; pharmacoeconomic evaluations; traceability, nomenclature, and coding; education; and pharmacovigilance.

show abstract

“…As can be seen, after the approval of the protocol, the rate of drug use in third-level indications (C-Off-labeled without support), which are our main goal in reducing irrational IVIG consumption, decreased by 98.54%, which shows the significant success of the implemented protocol. Health providers in the implanting program will be able to prevent unsuitable medication use if they are able to comprehend the factors that influence the medications' misapplication, and medication use evaluation (MUE) is the cornerstone in this manner [23]. Limited worldwide accessibility of IVIG, escalating costs, and increasing the demands for unlicensed utilization, in addition to probable adverse reactions and insufficient information for the application of IVIG, particularly in the Middle Ebrahimi et al…”

Section: C-off-labeled Without Supportmentioning

confidence: 99%